Abstract
Pyridazin-3(2H)-one derivatives have attracted the attention of medicinal chemists during the last decade due to their diverse pharmacological activities. Easy functionalization of various ring positions of pyridazinones makes them an attractive synthetic building block for designing and synthesis of new drugs. The incorporation of this versatile biologically accepted pharmacophore in established medicinally active molecules results in wide range of pharmacological effects. Pyridazinones constitute an interesting group of compounds, many of which possess wide spread pharmacological properties such as antihypertensive, platelet aggregation inhibitory, cardiotonic activities and some are also well known for their pronounced analgesic, anti-inflammatory, antinociceptive, and antiulcer activities. Recently pyridazinones have also been reported as antidiabetic, anticonvulsant, antiasthmatic, and antimicrobial agents. These encouraging reports suggest that this privileged skeleton should be extensively studied for the therapeutic benefits. In view of this, a detailed and updated account of the pharmacological properties of pyridazinones is described in this review. The wide range of synthesized pyridazinone analogs along with their medicinal significance is also presented.
Similar content being viewed by others
References
Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H (2002) Levosimendan increases L-type Ca2+ current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol 435:27–33
Allen JR, George R, Hanifin JR, John W, Moran DB, Albright J (1985) Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as antiasthma agents. United States Patent 451591
Bansal R, Kumar D, Carron R, Calle CDL (2009) Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethyloxyphenyl)-4,5-dihydro-3(2H)-pyridazinone. Eur J Med Chem 44:4441–4447
Barbaro R, Betti L, Botta M, Corelli F, Giannaccini G, Maccari L, Manetti F, Strappaghetti G, Corsano S (2001) Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity towards α1- and α2-adrenoceptors. J Med Chem 44:2118–2132
Betti L, Floridi M, Giannaccini G, Manetti F, Strappaghetti G, Tafi A, Botta M (2003) α1-Adrenoceptor antagonists. pyridazinone-arylpiperazines, probing the influence on affinity and selectivity of both ortho-alkoxy groups at the arylpiperazine moiety and cyclic substituents at the pyridazinone nucleus. Bio Org Med Chem Lett 13:171–173
Biagini P, Biancalani C, Graziano A, Cesari N, Giovannoni MP, Cilibrizzi A, Dal Piaz V, Vergelli C, Crocetti L, Delcanale M, Armani E, Rizzi A, Puccini P, Gallo PM, Spinabelli D, Caruso P (2010) Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: synthesis and evaluation of their phosphodiesterase 4 inhibitory activity. Bioorg Med Chem Lett 18:3506–3517
Bowman P, Haikala H, Paul RJ (1999) Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 288:316–325
Bristol JA, Sircar I, Moos WH, Evans DB, Weishaar RE (1984) Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem 27:1099–1101
Cao S, Qian X, Song G, Chai B, Jaang Z (2003) Synthesis and antifeedant activity of new oxadiazolyl 3(2H)-pyridazinones. J Agri Food Chem 51:152–155
Chen HZ, Cui XL, Zhao HC, Zhao LY, Lu JY, Wu BW (2004a) Inotropic effects of MCI-154 on rat cardiac myocytes. Sheng Li Xue Bao 56:301–305
Chen H, Cui X, Guo W, Zhao H, Zhao L, Lu J, Wu B (2004b) Positive inotropic effect of MCI-154 on hypertrophied heart of rats and its mechanisms. Zhongguo Yaolixue Yu Dulixue Zazhi 18:338–343
Cherng SC, Huang HW, Shiau CY, Lee AR, Chou TC (2006) Mechanisms of antiplatelet activity of PC-09: a newly synthesized pyridazinone derivative. Eur J Pharmacol 532:32–37
Chintakunta VK, Akella V, Vedula MS, Mamnoor PK, Mishra P, Casturi SR, Vangoori A, Rajagopalan R (2002) 3-O-substituted benzyl pyridazinone derivatives as COX inhibitors. Eur J Med Chem 37:339–347
Cinone N, Carrieri G, Strappaghetti G, Corsano S, Barbaro R, Carotti A (1999) Comparative molecular field analysis of some pyridazinone-containing α1-anatagonists. Bio Org Med Chem 7:2615–2620
Coates WJ (1996) Pyridazines and their benzo derivatives. In: Katritzky AR, Rees CW, Scriven EFW (eds) Comprehensive heterocyclic chemistry, vol 6. Pergamon Press, Oxford, New York, pp 86–89
Combs DW, Rampulla MS, Bell SC, Klaubert DH, Tobia AJ, Falotico R, Haertlein B, Moore JB (1990) 6-Benzoxazinyl- pyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents. J Med Chem 33:380–386
Costantino L, Rastelli G, Gamberini MC, Giovannoni MP, Dal Piaz V, Vianello P, Barlocco D (1999) Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. J Med Chem 42:1894–1900
Curran CV, Ross A (1974) 6-Phenyl-4,5-dihydro-3(2H)-pyridazinones. A series of hypotensive agents. J Med Chem 17:273–281
Dal Piaz V, Ciciani G, Giovannoni MP (1994) 4,5-Functionalized-3(2H)-pyridazinones: new synthetic and pharmacological aspects. Acta Chim Slov 41:189–203
Dal Piaz V, Giovannoni MP, Ciciani G, Barlocco D, Giardina G, Petrone G, Clarke GD (1996) 4,5-Functionalized 6-phenyl-3(2H)-pyridazinones: synthesis and evaluation of antinociceptive activity. Eur J Med Chem 31:65–70
Dal Piaz V, Rascon A, Dubra ME, Giovannoni MP, Vergelli C, Castellana MC (2002) Isoxazolo[3,4-d]pyridazinones and analogues as Leishmania mexicana PDE inhibitors. IL Farmaco 57:89–96
Dal Piaz V, Vergelli C, Giovannoni MP, Scheideler MA, Petrone G, Zaratin P (2003) 4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity. IL Farmaco 58:1063–1071
Demirayak S, Karaburun AC, Beis R (2004) Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. Eur J Med Chem 39:1089–1095
Dogruer DS, Sahin ME (2003) Synthesis, analgesic and anti-inflammatory activity of new pyridazinones. Turk J Chem 27:727–738
Fitton A, Brogden RN (1994) Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging 4:417–441
Giovannoni MP, Dal Piaz V, Kwon BM, Kim MK, Toma L, Kwon BM, Kim MK, Kim YK, Toma L, Barlocco D, Bernini F, Canavesi M (2001) 5,6-Diphenylpyridazine derivatives as Acyl-CoA: cholesterol acyltransferase inhibitors. J Med Chem 44:4292–4295
Gokce M, Dogruer D, Sahin MF (2001) Synthesis and antinociceptive activity of 6-substituted-3-pyridazinone derivatives. IL Farmaco 56:233–237
Gokce M, Sahin MF, Kupeli E, Yesilada E (2004) Synthesis and evaluation of the analgesic and anti-inflammatory activity of new 3(2H)-pyridazinone derivatives. Arzneim-Forsch 54:396–401
Gokce M, Utku S, Kupeli E (2009) Synthesis and analgesic and anti-inflammatory activities 6-substituted-3(2H)- pyridazinone-2-acetyl-2-(p substituted /nonsubstituted benzal) hydrazone derivatives. Eur J Med Chem 44:3760–3764
Harris R, Black L, Surapaneni S, Kolasa T, Majest S (2004) ABT-963 [2-(3,4-Difluorophenyl)-4(3-hydroxy-3-methylbutoxy)-5-(4-methanesulphonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxygenase-2 inhibitor. J Pharmacol Exp Ther 311:904–912
Heinisch G, Frank H (1990) Pharmacologically active pyridazine derivatives. Part 2. In: Ellis GP, West GB (eds) Progress in medicinal chemistry, 27th edn. Elsevier, Amsterdam, p 1
Heinisch G, Frank H (1992) Pharmacologically active pyridazine derivatives. Part 2. In: Ellis GP, West GB (eds) Progress in medicinal chemistry, 29th edn. Elsevier, Amsterdam, pp 141–183
Innes CA, Wagstaff AJ (2003) Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 63:2651–2671
Jiang Q, Hu D, Xiao N, Du W, Liu R, Min J, Wang Q, Liu L (2002) Therapeutic effect of 6-[4-(4’-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone on hemorrhagic shock and its mechanisms in rabbits and rats. Zhongguo Yaolixue Yu Dulixue Zazhi 16:102–105
Kasikcioglu HA, Cam N (2006) A review of levosimendan in the treatment of heart failure. Vasc Health Risk Manag 2:389–400
Kawasumi H, Abe Y, Ishibashi A, Kitada Y (1999) MCI-154, a Ca2+ sensitizer, increases survival in cardiomyopathic hamsters. Eur J Pharmacol 372:175–178
Kerdesky FA, Leanna MR, Zhang JI, Wenke LI, Lallaman JE, Jianguo JI, Morton HE (2006) An efficient multikilogram synthesis of ABT-963: a selective COX-2 inhibitor. Org Pro Res Dev 10:512–517
Kitada Y, Kobayashi M, Narimatsu A, Ohizumi Y (1989) Potent stimulation of myofilament force and adenosine triphosphatase activity of canine cardiac muscle through a direct enhancement of troponin C calcium binding by MCI-154, a novel cardiotonic agent. J Pharmacol Exp Ther 250:272–277
Korvald C, Nordhaug DO, Steensrud T, Aghajani E, Myrmel T (2002) Vasodilation and mechanoenergetic inefficiency dominates the effect of the “Ca2+-sensitizer” MCI-154 in intact pigs. Scand Cardiovasc J 36:172–179
Kubo SH (1997) Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Cardiology 88:21–27
Kumar D, Carron R, La Calle CD, Jindal DP, Bansal R (2008) Synthesis and evaluation of 2-substituted-6-phenyl-4,5-dihydropyridazin-3(2H)-ones as potent inodilators. Acta Pharm 4:393–405
Laguna R, Montero A, Cano E, Ravina E, Sotelo E, Estevez I (1996) 6-Aryl-5-substituted pyridazinones as platelet aggregation inhibitors with non cAMP PDE-3 based mechanism. Acta Pharma Hung 66:S43–S45
Lazewska D, Kiec-Kononowicz K (2010) Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 20:1147–1169
Lee SG, Kim JJ, Kweon DH, Kang YJ, Cho SD, Kim SK, Yoon YJ (2004) Recent progress in pyridazin-3(2H)-ones chemistry. Curr Med Chem 8:1463–1480
Malinka W, Redzicka A, Lozach O (2004) New derivatives of pyrrolo[3,4-d] pyridazinone and their anticancer effects. IL Farmaco 59:457–462
Malinka W, Redzicka A, Jastrzębska-Więsek M, Filipek B, Dybała M, Karczmarzyk Z, Urbańczyk-Lipkowska Z, Kalicki P (2011) Derivatives of pyrrolo[3,4-d]pyridazinone, a new class of analgesic agents. Eur J Med Chem 46:4992–4999
Manetti F, Corelli F, Strappaghetti G, Botta M (2002) Arylpiperazines with affinity towards α1-adrenergic receptors. Curr Med Chem 9:1303–1321
Margaretha VM, Bommele KM, Boss H, Hatzelmann A, Slingerland MV, Sterk GJ, Timmerman H (2003) Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 46:2008–2016
Mathieu S, Crai G (2011) Levosimendan in the treatment of acute heart failure, cardiogenic and septic shock: a critical review. J Iran Chem Soc 12:1
Matyus P (1998) 3(2H)-Pyridazinones: some recent aspects of synthetic and medicinal chemistry. J Het Chem 35:1075–1089
Matyus p, Czako K (1993) 4,5-Dihalo-3(2H)-pyridazinones—regiochemistry and synthetic utility for fused pyridazine derivatives. Trends Heterocyclic Chem 3:249–264
Meade EA, Wortin LL, Drach JC, Townsend LB (1993) Synthesis, antiproliferative and antiviral activity of 4-amino-1(β-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives. J Med Chem 36:3834–3842
Miyake S, Shiga H, Koike H (1989) Arterial and venous vasodilator actions of RS-1893, a novel cardiotonic agent, in the hind limb preparation of the dog. J Cardiovasc Pharmacol 14:526–533
Montesano F, Barlocco D, Dal Piaz V, Leonardi A, Poggesi E, Fanelli F (1998) Isoxazolo-[3,4-d]-pyridazin-7-(6H)-ones and their corresponding 4,5-disubstituted-3-(2H)-pyridazinone analogues as new substrates for α1-adrenoceptor selective antagonists: synthesis, modeling and binding studies. Bio Org Med Chem 6:925–935
Mylari BL, Armento SJ, Beebe DA, Conn EL, Coutcher JB, Dina MS (2003) A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one. J Med Chem 46:2283–2286
Narimatsu A, Kitada Y, Satoh N, Suzuki R, Okushima H (1987) Cardiovascular pharmacology of 6-[4-(4’-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. Arzneim-Forsch 37:398–406
Purohit DM, Shah VH (1998) Novel method for synthesis and antimicrobial activity of 2-arylsulpho-6-hydroxy/chloro/hydrazine/carboxy-methoxy-3(2H)-pyridazinones. Ind J Chem 37:956–960
Rathish IG, Javed K, Bano S, Ahmad S, Alam MS, Pillai KK (2009) Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzene sulfonylurea derivatives. Eur J Med Chem 44:2673–2678
Regina MB (2006) Cyclooxygenase: past, present and future. J Therm Biol 31:208–219
Rohet E, Rubat C, Coudert P, Albuisson E, Couquelet J (1996) Synthesis and trazodone like analgesic activity of 4-phenyl-6-aryl-2-[3-(4-arylpiperazin-1-yl)propyl]pyridazin-3-ones. Chem Pharm Bull 44:980
Rossotti R, Rusconi S (2009) Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1. HIV Therapy 3:63–77
Rubat C, Coudert P, Tronche P, Bastide J, Bastide P, Privat AM (1989) Synthesis and pharmacological evaluation of N-substituted 4,6-diaryl-3-pyridazinones as analgesic, anti-inflammatory and antipyretic agents. Chem Pharm Bull 37:2832–2835
Rubat C, Coudert P, Albuisson E, Bastide J, Couquelet J, Tronche P (1992) Synthesis of Mannich bases of aryldenepyridazinones as analgesic agents. J Pharm Sci 81:1084
Santagati NA, Duro E, Caruso A, Trombadore S, Amico-Roxas M (1985) Synthesis and pharmacological study of a series of 3(2H)-pyridazinones as analgesic and anti-inflammatory agents. IL Farmaco 40:921
Sata M, Sugiura S, Yamashita H, Fujita H, Momomura S, Serizawa T (1995) MCI-154 increases Ca2+ sensitivity of reconstituted thin filament. A study using a novel in vitro motility assay technique. Circ Res 76:626–633
Schudt C, Winder S, Mueller B, Ukena D (1991) Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol 42:153–162
Siddiqui AA, Mishra R, Shaharyar M (2010) Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. Eur J Med Chem 45:2283–2290
Sivakumar R, Anabalagan N, Gunasekaran V, Leonard JT (2003) Synthesis and anticonvulsant activity of novel 1-substituted-1,2-dihydro-pyridazine-3,6-diones. Biol Pharm Bull 26:1407–1411
Sonmej M, Berber L, Akbas B (2005) Synthesis, antibacterial and antifungal activity of some new pyridazinone metal complexes. Eur J Med Chem 41:101–105
Steuber H, Zentgraf M, Podjarny A, Heine A (2006) High-resolution crystal. Structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. J Mol Biol 356:45–56
Sukuroglu M, Ergun BC, Unlu M, Sahin MF, Kupeli E, Yesilada E, Banoglu E (2005) Synthesis, analgesic, and anti-inflammatory activities of [6-(3,5-dimethyl-4-chloropyrazole-1-yl)-3(2H)-pyridazinon-2-yl]acetamides. Arch Pharm Res 5:509–517
Tao M, Raddatz R, Aimone LD, Hudkins RL (2011) Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists. Bioorg Med Chem Lett 21:6126–6130
Tsubaki K, Taniguchi K, Tabuchi S, Okitsu O, Hattori K, Seki J, Sakane K, Tanaka H (2000) A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. Bio Org Med Chem Lett 10:2787–2790
Ungureanu M, Mangaalagiu I, Grasu G, Petrovanu M (1997) Antimicrobial activity of some new pyridazium compounds. Annal Pharm Franc 55:69–72
Warren SE, Kihara Y, Pesaturo J, Gwathmey JK, Phillips P, Morgan JP (1989) Inotropic and lusitropic effects of MCI-154 (6-[4-(4-pyridyl)-aminophenyl]-4,5-dihydro-3(2H)-pyridazinone) on the human myocardium. J Mol Cell Cardiol 21:1037–1045
Xu P, Wang SY, Chen Y, Liu WO, Tao C (1991) Studies on synthesis, anticonvulsant activity and the structure activity relationship of 6-(substitutedphenyl)-3(2H) pyridazinones. Yao Xue Xue Bao 26:656–660
Xu YJ, Zhao SY, Wang ZC, Liu SC, Sun WJ, Zhao SC (1999) New synthesis of cardiotonic agent pimobendan. Hecheng Huaxue 7:194–197
Yamada T, Nobuhara Y, Yamaguchi A, Ohki M (1982) Pyridazinones. 1. Synthesis and antisecretory and antiulcer activities of thioamide derivatives. J Med Chem 25:975–982
Yamada T, Nobuhara Y, Shimamura H, Tsukamoto Y, Yoshihara K, Yamaguchi A, Ohki M (1983a) Pyridazinones. 2. Synthesis and antisecretory and antiulcer activities of thiourea and 2-cyanoguanidine derivatives. J Med Chem 26:373–381
Yamada T, Shimamura H, Tsukamoto Y, Yamaguchi A, Ohki M (1983b) Pyridazinones. 3. Synthesis and antisecretory and antiulcer activities of 2-cyanoguanidine derivatives. J Med Chem 26:1144–1149
Zhou G, Ting PC, Aslanian R, Cao J, Kim DW, Kuang R, Lee JF, Schwerdt J, Wu H, Herr AJ, Yang J, Lam S, Wainhaus S, Black TA, Mcnicholas PM, Xu Y, Walker SS (2011) SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors. Bioorg Med Chem Lett 21:2890–2893
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bansal, R., Thota, S. Pyridazin-3(2H)-ones: the versatile pharmacophore of medicinal significance. Med Chem Res 22, 2539–2552 (2013). https://doi.org/10.1007/s00044-012-0261-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-012-0261-1